Revive Therapeutics Ltd (RVVTF)

[Obtuse Eye]

Could he have possibly been told that what they had *might* work if the data was good enough?

I think about those things as well. Why all of a sudden stop at 712? I think that was answered in a round about way.

Why the holdup on running the information to the DSMB and FDA, IF it was ever determined that the 712 tested patients MAY be enough?

Where was/why the hangup between unblinding the first set of data (and scrubbing the rest of it), until getting the next steps to push forward?

So, I find it not AT ALL surprising when I see the news that the status will change May 11th, and that HHS (another gov't entity) controls the say-so on when EUA approvals through the FDA will end.

Yes, I blame Revive for being a poor company and not necessarily having the full wherewithal for pushing their trials more aggressively. But a much higher percentage of that blame (in my mind) is bound up with red tape.